- Michaela J. Higgins, Mb.Bch, Bao
- Identify molecular pathways that contribute to endocrine and trastuzumab resistance and discuss their implications for treatment.
- Discuss the outcomes of the most recent clinical trials related to the management of women with treatment-resistant breast cancer, including those with triple-negative breast cancer.
Instructor in Medicine, Massachusetts General Hospital and Harvard Medical School
Release Date: October 5, 2012
Review: October 18, 2013
Expiration Date: October 4, 2014
On Demand Event Details
To receive credit for the webinar, you must view the presentation and complete the post-test and activity evaluation. Upon completion, you will be able to receive one credit.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The Society for Translational Oncology (STO) and Massachusetts General Hospital. The Society for Translational Oncology (STO) is accredited by the ACCME to provide continuing medical education (CME) for physicians.
STO designates this enduring material for a maximum of one (1) AMA PRA Category 1 Credit TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Policy on Faculty and Provider Disclosure
It is the policy of The Society for Translational Oncology (STO) that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity. The Society for Translational Oncology (STO) has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.
FACULTY DISCLOSURE STATEMENTS
In accord with the disclosure policy of The Society for Translational Oncology (STO) as well as guidelines of the Accreditation Council for Continuing Medical Education (ACCME), planners, speakers and anyone who may have an influence on the content of the activity have been asked to disclose any relationship they or their spouse/partner have to companies producing pharmaceuticals, medical equipment, devices, etc. that may be germane to the content of their presentation. Such disclosure is not intended to suggest or condone bias, but provides participants with information that might be of potential importance to their evaluation of a given presentation.
Independent Peer Reviewer Disclosure
Reviewer “A” discloses no relevant financial relationships.
Robert J. Birnbaum, MD, PhD
Anan Nathif, EdM
Beverly Moy, MD
The following speaker of this activity has indicated that neither she nor her spouse/partner have a relevant financial relationship to disclose:
Michaela J. Higgins, Mb.Bch
- Genomic Health
Optimal System Configuration:
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher
500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit
This program has received support in the form of educational grants from the following companies: